ArticleNano today2011
In Vivo Modulation of Dendritic Cells by Engineered Materials: Towards New Cancer Vaccines.
Article in Nano today, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Enhancing radiotherapy-induced anti-tumor immunity via nanoparticle-mediated STING agonist synergy.Molecular cancer · 2025Review
- From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.International journal of molecular sciences · 2024Review
- Biomaterials Facilitating Dendritic Cell-Mediated Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy.Advanced materials (Deerfield Beach, Fla.) · 2023Review
- Rational Vaccinology: Harnessing Nanoscale Chemical Design for Cancer Immunotherapy.ACS central science · 2022Review
- Article
- Article
- An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine.Pharmaceutics · 2021Review
- Review
- Lactate Exposure Promotes Immunosuppressive Phenotypes in Innate Immune Cells.Cellular and molecular bioengineering · 2020Article
- Developing immune-regulatory materials using immobilized monosaccharides with immune-instructive properties.Materials today. Bio · 2020Article
- Tumor cell lysate-loaded immunostimulatory spherical nucleic acids as therapeutics for triple-negative breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Properties of immature and mature dendritic cells: phenotype, morphology, phagocytosis, and migration.RSC advances · 2019Article
- Injectable Biodegradable Chitosan-Alginate 3D Porous Gel Scaffold for mRNA Vaccine Delivery.Macromolecular bioscience · 2019Article
- Enhanced anti-tumor immunotherapy by silica-coated magnetic nanoparticles conjugated with ovalbumin.International journal of nanomedicine · 2019Article
- Extra-Large Pore Mesoporous Silica Nanoparticles Enabling Co-Delivery of High Amounts of Protein Antigen and Toll-like Receptor 9 Agonist for Enhanced Cancer Vaccine Efficacy.ACS central science · 2018Article
- Self-assembled PEG-Regenerative biomaterials · 2017Article
- Proteomic composition and immunomodulatory properties of urinary bladder matrix scaffolds in homeostasis and injury.Seminars in immunology · 2017Review
- Programmable biomaterials for dynamic and responsive drug delivery.Experimental biology and medicine (Maywood, N.J.) · 2016Review
- Developing a pro-regenerative biomaterial scaffold microenvironment requires T helper 2 cells.Science (New York, N.Y.) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Therapeutic cancer vaccines are emerging as novel and potent approaches to treat cancer. These vaccines enhance the body's immune response to cancerous cells, and dendritic cells (DCs), an initiator of adaptive immunity, are a key cell type targeted by these strategies. Current DC-based cancer vaccines are based on ex vivo manipulation of the cells following their isolation from the patient, followed by reintroduction to the patient, but this approach has many limitations in practical cancer treatment. However, recent progress in materials science has allowed the design and fabrication of physically and chemically functionalized materials platforms that can specifically target DCs in the body. These materials, through their in vivo modulation of DCs, have tremendous potentials as new cancer therapies. Nanoparticles, which are several orders of magnitude smaller than DCs, can efficiently deliver antigen and danger signals to these cells through passive or active targeting. Three-dimensional biomaterials, with sizes several orders of magnitude larger than DCs, create microenvironments that allow the effective recruitment and programming of these cells, and can be used as local depots of nanoparticles targeting resident DCs. Both material strategies have shown potential in promoting antigen-specific T cell responses of magnitudes relevant to treating cancer.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.